| Private Placement / Financing Transactions
Avalyn Pharma: The company raised $189.2 million of Series C venture funding in a deal led by SR One Capital Management, Eventide Asset Management and Perceptive Advisors on October 10, 2023. Vida Ventures, RiverVest Venture Partners, Norwest Venture Partners, F-Prime Capital, Pivotal bioVenture Partners, Catalio Capital Management, Piper Heartland, Novo Holdings, Wellington Management, Rock Springs Capital and Surveyor Capital also participated in the round. The company is a developer of novel therapies technology designed for the treatment of idiopathic pulmonary fibrosis and severe respiratory diseases.
SHINE Technologies: The company received $70 million of development capital from Fidelity Management & Research, Baillie Gifford and other undisclosed investors on October 11, 2023. The company is a developer of medical isotopes intended to serve energy, aerospace, manufacturing, medicine and nuclear industries.
AgomAb Therapeutics: The company raised $100 million of Series C venture funding in a deal led by Fidelity Management & Research on October 11, 2023. Dawn Biopharma, Canaan Partners and EQT Life Sciences also participated in the round. The company is a developer of agonistic antibodies designed to help in the regeneration of damaged tissues.
PanTheryx: The company received $52.3 million of development capital from Pegasus Capital Advisors on October 11, 2023. The company is a provider of intestinal research and medical nutrition products intended to address gastrointestinal microbiome-related health conditions.
CuraSen: The company raised $17.6 million of Series A venture funding from undisclosed investors on October 11, 2023. The company is an operator of a biopharmaceutical business intended for the development of novel treatments for neurodegenerative diseases.
Synerkine Pharma: The company raised EUR 12.1 million of Series A venture funding in a deal led by Flerie on October 12, 2023. Thuja Capital Management, Utrecht Holdings and IQCapital also participated in the round. The company is a developer of fusion proteins designed to help in the treatment of inflammatory, neuropathic, and osteoarthritic pain.
Cionic: The company raised $12 million of venture funding from undisclosed investors on October 13, 2023. The company is a developer of neural sleeves designed to give those with conditions such as MS more mobility.
Tilak Healthcare: The company raised EUR 10 million of venture funding led by Elaia Partners & Cap Horn Finance, and participated by Adelie and iBionext, on October 12, 2023. Yann Fleureau and other undisclosed investors also participated in the round. The company is a developer of mobile medical games designed to remotely monitor vision parameters of patients suffering from chronic maculopathies.
LyGenesis: The company raised $8.7 million of venture funding from undisclosed investors on October 12, 2023. The company is a developer of a cell therapy technology designed to facilitate organ regeneration and transplant.
Window Therapeutics: The company raised $7.5 million of venture funding from undisclosed investors on October 13, 2023. The company develops transformational therapeutics to address unmet patient needs in cancer and other life-threatening diseases.
Apollo: The company raised $6 million of venture funding in the form of SAFE notes from Portfolia and other undisclosed investors on October 12, 2023. The company is a developer of a wearable device designed to improve the body’s resilience to stress.
Starton Therapeutics: The company raised $3.4 million of venture funding from undisclosed investors on October 11, 2023. Starton Therapeutics Inc is a clinical-stage biotechnology company that provides standard-of-care therapies with proprietary continuous delivery technology for people with cancer.
iQure Pharma: The company raised $2.9 million in Series A venture funding in a deal led by Ventura BioMed Investors on October 11, 2023, putting the company’s pre-money valuation at $6.1 million. OKG Capital, Keiretsu Forum and other undisclosed investors also participated in the round. The company develops new therapeutics for neurodegenerative diseases with unmet medical needs.
Cirdan: The company raised GBP 2.3 million of venture funding in a deal led by Kernel Management Partners on October 12, 2023. Clarendon Fund Managers and other undisclosed investors also participated in the round. The company is a developer of healthcare informatics software designed to offer imaging technology to accelerate and enhance diagnosis.
Spine BioPharma: The company raised $2.4 million of venture funding in the form of equity and convertible notes from undisclosed investors on October 11, 2023. The company is a developer of non-surgical therapies intended to reduce pain, restore function, and slow or stop pathological spinal disease progression without the use of opioids.
|
